Single-dose Russian vaccine with 70% efficacy against Delta variant


Sedat Sun / EPA

The Russian single-dose covid-19 vaccine, Sputnik Light, is 70% effective against the Delta variant of the SARS-CoV-2 coronavirus three months after inoculation, a laboratory in that country announced today.

According to the Russian Gamaleya Center for Epidemiology and Microbiology, which developed this version of the two-dose Sputnik V vaccine, studies indicate that Sputnik Light also showed a effectiveness greater than 75% in people under 60 years of age.

This research center and the Russian Direct Investment Fund (FRID), which markets Russian vaccines abroad, ensured that the effectiveness of Sputnik Light “is superior compared to some two-dose vaccines, which have shown a significant decrease in their effectiveness – up to 50% – against the Delta variant five months after inoculation”.

The position of these entities is based on data from 28 thousand people who received the single dose when compared to a control group of 5.6 million citizens who have not been vaccinated against covid-19.

The Gamaleya center also stated that the effectiveness of Sputnik Light as a booster for other vaccines against the Delta variant is close to that of two-dose Sputnik V, proving to be 83% efficient at preventing coronavirus infection and more than 94% to prevent hospitalization.

This single-dose vaccine has been authorized so far in about 15 countries and will be produced in more than ten countries, such as China, India, South Korea, Mexico, Argentina and Turkey, among others.

On May 6, the FRID, which finances the development of Russian vaccines, announced the approval of Sputnik Light, which is not authorized in the European Union.